Table 1.
Relationship between Transcription Level of GNA15 and Clinical Characteristics in Normal Karyotype AML.
| Variables | Total | L-GNA15 | H-GNA15 | P-value |
|---|---|---|---|---|
| N = 50 | N = 27 | N = 23 | ||
| Age,years | ||||
| Mean ± SD | 43.9 ± 15.8 | 39.4 ± 15.5 | 49.3 ± 14.7 | 0.024 |
| ≥60, n (%) | 7 (14) | 2 (7.4) | 5 (21.7) | 0.295 |
| Female, n (%) | 28 (56.0) | 16 (59.3) | 12 (52.2) | 0.615 |
| Risk group, n (%) | 0.868 | |||
| Low | 10 (20) | 6 (22.2) | 4 (17.4) | |
| Medium | 20 (40) | 10 (37.0) | 10 (43.5) | |
| High | 20 (40) | 11 (40.7) | 9 (39.1) | |
| PLT, ×109/l | 38 (4-260) | 29 (6-260) | 45 (4-218) | 0.453 |
| Hb, g/l | 85.3 ± 21.7 | 82.5 ± 19.4 | 88.5 ± 24.2 | 0.339 |
| Blast of BM (%) | 75.0 (0-99) | 75.0 (0-99) | 75.5 (0-94) | 0.016 |
| MRD of flow cytometry (%) | 0.7 (0-75.5) | 0.9 (0-26.9) | 0.9 (0-75.5) | 0.003 |
| Mutations, n (%) | ||||
| FLT3-ITD | 11 (22) | 5 (18.5) | 6 (26.1) | 0.520 |
| NPM1 | 6 (12) | 3 (11.1) | 3 (13.0) | 1.000 |
| CEBPA | 5 (10) | 3 (11.1) | 2 (8.7) | 1.000 |
| DNMT3A | 5 (10) | 4 (80) | 1 (20) | 0.449 |
| WT1 | 6.2 (0-86.9) | 0.5 (0-12.9) | 6.2 (5-86.9) | 0.000 |
| TET2 | 19 (38) | 12 (63.2) | 7 (36.8) | 0.309 |
| IDH1/2 | 8 (16) | 7 (87.5) | 1 (12.5) | 0.092 |
| RUNX1 | 2 (4) | 1 (50) | 1 (50) | 1.000 |
| Transplant, n (%) | 11 (22) | 8 (29.6) | 3 (13.0) | 0.285 |
H-GNA15, high GNA15 expression; L-GNA15, low GNA15 expression; SD, standard deviation; PLT, platelet; Hb, hemoglobin; BM, bone marrow; MRD, minimal residual disease.